$Fate Therapeutics(FATE.US)$ Fate Therapeutics to Present at 2024 Jefferies Global Healthcare Conference Fate Therapeutics, a clinical-stage biopharmaceutical company focusing on iPSC-derived cellular immunotherapies for cancer and autoimmune diseases, announced their participation in the 2024 Jefferies Global Healthcare Conference. The presentation is scheduled for June 5, 2024, at 3:00 PM ET in New York. The event will be webcasted live and accessible on the Company’s website, with an arch...
Fate Therapeutics股票讨论区
Fate Therapeutics to Present at 2024 Jefferies Global Healthcare Conference
Fate Therapeutics, a clinical-stage biopharmaceutical company focusing on iPSC-derived cellular immunotherapies for cancer and autoimmune diseases, announced their participation in the 2024 Jefferies Global Healthcare Conference. The presentation is scheduled for June 5, 2024, at 3:00 PM ET in New York. The event will be webcasted live and accessible on the Company’s website, with an arch...
新闻
Fate Therapeutics 宣布在现成的 FT819 CAR T 细胞计划 1 期自身免疫研究中首次接受治疗的狼疮患者
⇨ 由5家专注于生物制药的对冲基金持有!🔥
$Arcellx(ACLX.US)$ : Anito-cel(第 2 阶段)
$Adaptimmune Therapeutics(ADAP.US)$ : Afami-cel (PDUFA) ⏳
$Bicycle Therapeutics(BCYC.US)$ : BT8009(第 1/2 页)
$Centessa Pharmaceuticals(CNTA.US)$ : LB101(第 1/2 页)
$Day One Biopharmaceuticals(DAWN.US)$ : Tovorafenib (PDUFA)(详情请查看评论)
$Fate Therapeutics(FATE.US)$ : FT576(第 1 阶段)
$Fusion Pharmaceuticals(FUSN.US)$ : FPI-2265(第 2 阶段)
$GRCL:...
道琼斯· 1 分钟前
暂无评论